bioskin.GIF

OTHER SCIENTIFIC PUBBLICATIONS

General bibliographical data on the Vitiligine and relative to the terapeutica usefullness of beams UVB.

  1. Lotti T, Menchini G, Andreassi L. UV-B radiation Microphotopherapi (BIOSKIN®) J Europ Acad Dermatol Venereol, 1999: 13:1-7
     
  2. Menchini G, Lotti T. Microfototerapia UV-B (BIOSKIN®) Current int. 1999; 2:16-20
     
  3. Westerhof W, Nieuweboer-Krobotova L Trattamento della vitiligine con radiazioni UV-B contro il trattamento a base di psoralenici topici e UV-A. Arch Dermatol 1997 Dec;133(12):1525-8
     

  4. Njoo MD, Spuls PI, Bos JD, Westerhof W, Bossuyt PM. Terapie ripigmentanti non chirurgiche per la vitiligine. Uno studio metanalitico della letteratura. Arch Dermatol 1997 Dec;133(12):1525-8

  5. Salzer B, Schallreuter K. Investigation of the personality structure in patients with vitiligo and a possible association with catecholamine metabolism. Dermatology 1995; 190: 109-15.
  6. Kent G, Al'Abadie M. Psycologic effects of vitiligo: A critical incident analysis. J Am Acad Dermatol Dec. 1996; 35(6): 895-898.
  7. Fitzpatrick TB. Hypomelanosis. South Med J 1964;57: 995-1005.
  8. Ortonne JP. Le vitiligo: Maladie ou syndrome? [Thesis]. Lyon, France: Université de Lyon, 1974.
  9. Drake LA, et al. Guideline of care for vitiligo. J Am Acad Dermatol Oct. 1996; 35(4): 620-626.
  10. Hann SK, Lee HJ. Segmental vitiligo: Clinical findings in 208 patients. J Am Acad Dermatol Nov. 1996; 35(5) part1: 671-674.
  11. Barona MI, Arrunategui A, Falabella R, et al. An epidemiologic case-control study in a population with vitiligo. J Am Acad Dermatol Oct. 1995; 33(4): 621-625.
  12. Rook, Wilkinson, Ebling. Textbook of dermatology. Blackwell ed. 5th edition pp.582-590.
  13. Macaron C, Winter RJ, Traisman HS, et al. Vitiligo and juvenile diabetes mellitus. Arch Dermatol 1977; 113: 1515-17.
  14. Al'Abadie M, Alastair W, Bleehen S, et al. Morphologic observations on the dermal nerves in vitiligo: an ultrastructural study. Int J Dermatol Dec. 1995; 34(12): 837-840.
  15. Song YH, Connor E, Li Y, et al. The role of tyrosine in autoimmune vitiligo. Lancet 1994; 344: 1049-52.
  16. Gilhar A, Zelickson B, Ulman Y, et al. In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo. J Invest Dermatol Nov. 1995; 105(5): 683-686.
  17. Norris DA, Kissinger PM, Naughton GM, et al. Evidence for immunologic mechanism in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. J Invest Dermatol 1988; 90: 783-789.
  18. Ortonne JP, Alario A. T and B lymphocytes in vitiligo. Arch Dermatol Res 1978; 261: 147-51.
  19. Mozzanica N, Frigerio U, Finzi AF, et al. T-cell subpopulations in vitiligo: a chronobiologic study. J Am Acad Dermatol 1990; 22: 223-230.0
  20. Duram-Pierre DG, Walters CS, Halder RM, et al. Natural killer cell and lymphokine-activated killer cell activity against melanocytes in vitiligo. J Am Acad Dermatol Jul. 1995; 33(1): 26-30.
  21. Brethnach AS, Bor S, Wyllie L. Electron microscopy of peripheral nerve terminals and marginal melanocytes in vitiligo. J Invest Dermatol 1966; 47: 125-140.
  22. Mori H. Neurohistological studies on vitiligo vulgaris skin with special references to vegetative nerves. Jpn J Dermatol 1964; 74: 411-431.
  23. Nozaki T. Histochemical and electron-microscopy studies of peripheral nerves terminals and clinical studies in vitiligo vulgaris. Jpn J Dermatol 1976; 86: 1-19.
  24. Moore RY, Bloom FE. Central catecholamine neuron systems: anatomy and physiology of the norepinephrine and epinephrine systems. Ann Rev Neurosci 1979; 22: 113-168.
  25. Oehme P, Hecht K, Diesche L. Substance-P: new aspect of its modulatory function. Acta Biol Med Ger 1980; 39: 469-477.
  26. Al'Abadie M, Gawkrodger DJ, Senior HJ, Bleehen SS. Neuropathological studies in vitiligo. Br J Dermatol 1992; 127(40): 26.
  27. Fleischmann RA, Saltman DL, Stastny V, et al. Deletion of the c-kit protooncogene in the human developmental defect piebald trait. Proc Natl Acad Sci USA 1991; 88: 10885-9.
  28. Giebel LD, Spritz RA. Mutation of the kit (mast/stem cell growth factor receptor) protooncogene in human piebaldism. Proc Natl Acad Sci USA 1991; 88: 8696-9.
  29. Nordlund J, Ortonne JP. Vitiligo and depigmentation. Curr Probl Dermatol 1992; 4(1): 3-30.
  30. Norris A, Todd C, Graham A, et al. The expression of the c-kit receptor by epidermal melanocytes may be reduced in vitiligo. Br J Dermatol 1996; 134: 299-306.
  31. Maresca V, Roccella M, Roccella F, et al. Increased sensitivity to perioxidative agents as a possible pathogenic factor of melanocyte damage in vitiligo. J Invest Dermatol Sept. 1997; 109(3): 310-313.
  32. Simsek H. Interferon-induced vitiligo in a patient with chronic viral hepatitis C infection. Dermatology 1996; 193(1): 65-66.
  33. Selvaag E. Chloroquine-induced vitiligo-like depigmentation. Ann Trop Pediatr 1997; 17(1): 45-48.
  34. Brown-Harrell V. Apparent exacerbation of vitiligo syndrome in a patient with pulmonary Mycobacterium avium complex disease who received clofazimine therapy. Cli Infect Dis 1996; 22(3): 581-582.
  35. Henderson CA. Vitiligo complicating diphencyprone sensitization therapy for alopecia universalis. Br J Dermatol 1995; 133(3): 496-497.
  36. Koo SW. Vitiligo following radiotherapy for carcinoma of the breast. Br J Dermatol 1996; 135(5): 852-853.
  37. Lotti T, Menchini G, Comacchi C, Ghersetich I. Treatment Pearls from Europe. Dermatology Clinic 1998; 16:631-643

 

 
  OTHER INTERNET SITE DEDICATED TO PATHOLOGIES OF THE SKIN  
  Italiani

|Dermatologia.it| |Melanoma.it| |Centrosalute.it|  |lapsoriasi.org|

  
  English

|Vitiligo.it| |Dermatology.it|  |Centrosalute.it| |Vitiligo.us|

  
Française

|Vitiligo.it| |Centrosalute.it|
Español

|Vitiligo.it| |Centrosalute.it|